Article
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
14 Sept 2017
Abstract excerpt
expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
